Pasithea Therapeutics Corp (KTTA) Stock Forecast & Price Target

Compare

148 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KTTA Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Pasithea

Therapeutics Corp

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KTTA Stock 12 Month Forecast

Average Price Target

$3.00

▲(158.62% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Pasithea Therapeutics Corp in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 158.62% change from the last price of $1.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Oct<br/>2021","9":"Dec<br/>2021","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.6,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.6,"date":1638316800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.00

Average Price Target$3.00

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sara Nik

H.C. Wainwright

Buy

158.62%

Upside

Initiated

12/08/25

Pasithea Therapeutics initiated with a Buy at H.C. WainwrightPasithea Therapeutics initiated with a Buy at H.C. Wainwright

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sara Nik

H.C. Wainwright

Buy

158.62%

Upside

Initiated

12/08/25

Pasithea Therapeutics initiated with a Buy at H.C. WainwrightPasithea Therapeutics initiated with a Buy at H.C. Wainwright

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pasithea Therapeutics Corp

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+2.60%

initiated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +2.60% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+2.60%

initiated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +2.60% per trade.

1 Year

Sara NikH.C. Wainwright

Success Rate

1/1 ratings generated profit

Average Return

+2.60%

initiated a buy rating 17 days ago

Copying Sara Nik's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.60% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+2.60%

initiated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +2.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KTTA Analyst Recommendation Trends

Rating

Dec 21

Aug 22

May 23

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KTTA has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KTTA average Analyst price target in the past 3 months is 3.00.

Each month's total comprises the sum of three months' worth of ratings.

KTTA Financial Forecast

No data currently available

KTTA Earnings Forecast

Currently, no earnings data available.

No data currently available

KTTA Sales Forecast

Currently, no sales data available.

KTTA Stock Forecast FAQ

What is KTTA’s average 12-month price target, according to analysts?

Based on analyst ratings, Pasithea Therapeutics Corp’s 12-month average price target is 3.00.

What is KTTA’s upside potential, based on the analysts’ average price target?

Pasithea Therapeutics Corp has 158.62% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KTTA a Buy, Sell or Hold?

Pasithea Therapeutics Corp has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Pasithea Therapeutics Corp’s price target?

The average price target for Pasithea Therapeutics Corp is 3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 158.62% Increase from the current price of $1.16.

What do analysts say about Pasithea Therapeutics Corp?

Pasithea Therapeutics Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of KTTA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Pasithea Therapeutics Corp (KTTA) Stock Forecast & Price Target

KTTA Analyst Ratings

KTTA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pasithea Therapeutics Corp

KTTA Analyst Recommendation Trends

KTTA Financial Forecast

KTTA Earnings Forecast

KTTA Sales Forecast

KTTA Stock Forecast FAQ

Detailed List of Analyst Forecasts